Lovastatin
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <applet load="" size=" | + | <applet load="" size="[450,380]" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align="right" caption="Lovastatin, also known as Mevacor"/> |
===Better Known as: Mevacor=== | ===Better Known as: Mevacor=== | ||
* Marketed By: Merck & Co. <br /> | * Marketed By: Merck & Co. <br /> | ||
| Line 13: | Line 13: | ||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
| - | + | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | |
| - | + | <tr> | |
| - | + | <td style="width:100%; vertical-align:top;border-width:0px; border-style:inset"> | |
| - | + | <div style="height:100%; width: 100%"> | |
| - | + | {{:Statin Pharmacokinetics}} | |
| - | + | </div> | |
| - | + | </td> | |
| - | + | </tr> | |
| - | + | </table> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
===References=== | ===References=== | ||
Revision as of 08:58, 10 December 2010
|
Better Known as: Mevacor
- Marketed By: Merck & Co.
- Major Indication: Hyperlipidemia & High Cholesterol (Hypercholesterolemia)
- Drug Class: HMGR Inhibitor or Statin
- Date of FDA Approval (Patent Expiration): 1991 (2001)
- 2000 Sales: $520 Million
- Importance: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: the article
- See Pharmaceutical Drugs for more information about other drugs and disorders
Mechanism of Action
Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of HMG-CoA Reductase (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.[1]
Pharmacokinetics
For References, See References |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995 Jan;31(1):9-27. PMID:7784310
